BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) Head-To-Head Comparison

GSK (NYSE:GSK) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Risk and Volatility

GSK has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Insider & Institutional Ownership

15.7% of GSK shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares GSK and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
BeOne Medicines	10.70%	14.23%	7.82%

Analyst Ratings

This is a summary of recent recommendations and price targets for GSK and BeOne Medicines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2	7	1	1	2.09
BeOne Medicines	1	1	12	3	3.00

GSK currently has a consensus price target of $56.50, indicating a potential upside of 10.66%. BeOne Medicines has a consensus price target of $402.71, indicating a potential upside of 13.93%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than GSK.

Valuation & Earnings

This table compares GSK and BeOne Medicines”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$33.20 billion	3.11	$7.54 billion	$3.20	15.96
BeOne Medicines	$5.34 billion	7.26	$286.93 million	$5.68	62.23

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats GSK on 9 of the 15 factors compared between the two stocks.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.